Recent developments for Pulmatrix include strategic merger announcements with Cullgen Inc. and Eos Senolytix, efforts to advance mitochondrial therapies, and financial challenges including a significant revenue decline.

• Pulmatrix and Cullgen announced a strategic merger agreement in February 2026 to combine resources and capabilities [N4].
• In March 2026, Pulmatrix announced a merger agreement to acquire Eos Senolytix to advance mitochondrial therapies, with the stock price declining following the announcement [N2][N3].
• Pulmatrix reported a 100% revenue decline in Q2 2025, reflecting ongoing financial challenges [N5].
• A weekly industry update in March 2026 highlighted Pulmatrix’s merger activities and clinical progress within the broader biotech sector [N1].

Pulmatrix’s proprietary iSPERSE™ technology offers a differentiated platform for inhaled drug delivery, which could enable development of novel therapies addressing unmet needs in migraine and respiratory diseases. Strategic mergers with Cullgen Inc. and Eos Senolytix aim to broaden the company’s pipeline and capabilities, particularly in mitochondrial therapies. Strong liquidity ratios as of Q1 2026 provide a runway to advance development programs. If the mergers are consummated successfully, Pulmatrix could leverage combined resources and expertise to accelerate product development and commercialization efforts.

Pulmatrix has a history of recurring losses and reported no revenue in 2025, with a 100% revenue decline in Q2 2025. The company’s financial statements are prepared on a going concern basis, with substantial doubt about its ability to continue without successful capital raises or merger consummation. Failure to close the proposed mergers could lead to strategic uncertainty or dissolution. The company faces risks from geopolitical instability, economic conditions, and the challenges inherent in developing and commercializing novel inhaled therapies. Capital raising on favorable terms is uncertain, and ongoing negative cash flows may require curtailing operations.

Pulmatrix’s moat is centered on its proprietary iSPERSE™ dry powder inhalation technology, which is engineered to deliver small, dense particles with high dispersibility and efficient airway delivery. This platform technology can be applied across various drug substances and inhaler devices, potentially providing a competitive advantage in inhaled therapeutics. The company’s focus on unmet medical needs in migraine and respiratory diseases, combined with strategic mergers to enhance its pipeline, supports its position in a specialized niche. However, the company faces significant execution risks related to product development, regulatory approvals, and capital requirements.

• Going Concern and Capital Raising Risk: Pulmatrix has recurring losses and substantial doubt exists about its ability to continue as a going concern beyond one year from the financial statement date without successful capital raises or consummation of the proposed mergers. Failure to raise capital could force delays, reductions, or elimination of product development and commercialization efforts [S2].
• Merger Execution Risk: The company’s future operations are highly dependent on the successful closing of the proposed mergers with Cullgen Inc. and Eos Senolytix. There is no assurance the mergers will be consummated, and failure could lead to seeking other strategic alternatives or dissolution [S2][N2][N3][N4].
• Commercialization and Revenue Risk: Pulmatrix reported no revenues in 2025 and a 100% revenue decline in Q2 2025. Even if new products are commercialized, the company may not generate sufficient revenues to cover expenses or achieve profitability [S1][N5].
• Geopolitical and Economic Risks: Global economic and political instability, including conflicts and sanctions, could adversely affect Pulmatrix’s business, supply chain, partners, and customers, potentially disrupting operations [S2].

• Pulmatrix, Inc. is a biopharmaceutical company focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ dry powder delivery technology [S1][S2].
• The iSPERSE™ technology enables delivery of small, dense particles with efficient dispersibility to the airways and can be formulated with various drug substances and inhaler technologies [S1].
• Pulmatrix has entered into multiple merger agreements: a strategic merger with Cullgen Inc. announced in February 2026 [N4], and a merger agreement to acquire Eos Senolytix announced in March 2026 to advance mitochondrial therapies [N2][N3].
• The company’s principal source of revenue historically was from a collaboration and license agreement related to the development and commercialization of PUR1900 under the Cipla Agreement, but no revenues were recognized for the year ended December 31, 2025 [S1].
• Pulmatrix reported a net loss of approximately $1.17 million for the quarter ended March 31, 2026, with basic and diluted EPS of -$0.32 per share [S2].
• As of March 31, 2026, Pulmatrix had cash and cash equivalents of approximately $3.32 million and current assets of $4.49 million against current liabilities of $0.91 million, resulting in a current ratio of 4.96 and a cash ratio of 3.67, indicating strong short-term liquidity [S2].
• The company has a history of recurring losses and its financial statements are prepared on a going concern basis, with substantial doubt about its ability to continue as a going concern beyond one year from the financial statement date without successful capital raises or consummation of the merger [S2].
• Pulmatrix’s future operations are highly dependent on the successful closing of the proposed merger with Eos Senolytix; failure to consummate the merger may lead to seeking other strategic alternatives or dissolution [S2].
• The company’s revenues in recent years have been limited, with a 100% revenue decline reported in Q2 2025 [N5].
• Pulmatrix recognizes revenue under ASC 606 and ASC 808 standards, applying a five-step model to contracts with customers, including research and development services and license agreements [S1].
• The company’s research and development expenses include costs for clinical trials, third-party contractors, license fees, and stock-based compensation [S1].
• Pulmatrix faces risks related to geopolitical instability, economic conditions, and the ability to raise additional capital to fund operations and product development [S2].